scPharmaceuticals Inc. (SCPH) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SCPH currently has 52.8M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 5.5% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Oct 07, 2025 |
POS AM filing: This POS AM filing by scPharmaceuticals Inc. deregisters all unsold securities from three S-3 registration statements (333-277886, 333-254637, and 333-229120) due to the company's merger with MannKind Corporation on October 7, 2025, which terminated all offerings and sales of the Registrant's securities. |
53M | 0 |
| Oct 07, 2025 |
POS AM filing: This is a post-effective amendment to deregister any and all securities that remain unsold or otherwise unissued under Registration Statements on Form S-3 due to the merger with MannKind Corporation, which terminated the offerings and sales of the Registrant's securities. |
53M | 0 |
| Oct 07, 2025 |
POS AM filing: This POS AM filing from scPharmaceuticals Inc. relates to the deregistration of unsold securities from three previous S-3 registration statements (333-277886, 333-254637, and 333-229120) due to the merger with MannKind Corporation, which terminated all offerings and sales of the Registrant's securities. |
53M | 0 |
| May 14, 2025 |
10-Q filing | 52.8M shares outstanding |
53M | 0 |
| Mar 19, 2025 |
10-K filing | 50.3M shares outstanding |
50M | 0 |
| Nov 13, 2024 |
10-Q filing | 50.0M shares outstanding |
50M | 0 |
| Aug 14, 2024 |
10-Q filing | 50.0M shares outstanding |
50M | 0 |
| May 14, 2024 |
10-Q filing | 37.8M shares outstanding |
38M | 5.9M |
| Mar 13, 2024 |
S-3 filing: The company is filing an S-3 form to offer and sell up to $200,000,000 in aggregate principal amount of common stock, preferred stock, and debt securities, with common stock offered at $5.36 per share. The company will offer $50,000,000 in common stock in an 'at the market offering' to support commercialization efforts for FUROSCIX. |
36M | 7.7M |
| Mar 13, 2024 |
10-K filing | 36.1M shares outstanding |
36M | 7.7M |
| Nov 08, 2023 |
10-Q filing | 35.9M shares outstanding |
36M | 0 |
| Aug 10, 2023 |
10-Q filing | 35.9M shares outstanding |
36M | 0 |
| May 10, 2023 |
10-Q filing | 35.8M shares outstanding |
36M | 0 |
| Mar 22, 2023 |
10-K filing | 35.8M shares outstanding |
36M | 0 |
| Nov 09, 2022 |
10-Q filing | 27.4M shares outstanding |
27M | 7M |
| Aug 09, 2022 |
10-Q filing | 27.4M shares outstanding |
27M | 7M |
| May 16, 2022 |
10-Q filing | 27.4M shares outstanding |
27M | 7M |
| Mar 22, 2022 |
10-K filing | 27.4M shares outstanding |
27M | 7M |
| Nov 09, 2021 |
10-Q filing | 27.4M shares outstanding |
27M | 7M |
| Aug 11, 2021 |
10-Q filing | 27.4M shares outstanding |
27M | 7M |
| May 12, 2021 |
10-Q filing | 27.4M shares outstanding |
27M | 7M |
| Mar 23, 2021 |
10-K filing | 27.4M shares outstanding |
27M | 7M |
| Mar 23, 2021 |
S-3 filing: Shelf filing for the potential offering of common stock, preferred stock, and debt securities up to $150,000,000 in aggregate principal amount; also an ATM offering of common stock up to $50,000,000 at a price of $7.08 per share. |
27M | 7.1M |
| Nov 16, 2020 |
10-Q filing | 27.3M shares outstanding |
27M | 0 |
| Aug 13, 2020 |
10-Q filing | 27.3M shares outstanding |
27M | 0 |
| May 12, 2020 |
10-Q filing | 21.0M shares outstanding |
21M | 0 |
| Mar 24, 2020 |
10-K filing | 21.0M shares outstanding |
21M | 0 |